ScholarLens Back to search
2008•PubMedRequires access

[Safety of metformin in the treatment of elderly type 2 diabetes mellitus].

Hui Tian, Chunlin Li, Guang Yang, Yin-zhang Wang, Wen-yi Zong, Yinghong Shao, Shuangtong Yan, Jian Li, Junhua Huang, Yanping Gong, Min-yan Liu

Open publisher page 1 citations

Abstract

OBJECTIVE: To evaluate the safety of metformin in the treatment of elderly type 2 diabetes mellitus (T2DM). METHODS: Two hundred and forty-three cases of elderly T2DM hospitalized from Jan. 1996 to Dec. 2006 were reviewed; the changes of fasting blood glucose(FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), liver and renal function and blood lactic acid were evaluate before and after treatment. RESULTS: The mean time of treatment with metformin was (6.6 +/- 3.9) years (3 months - 21 years) in these 243 cases. The levels of FBG, PBG and HbA1c significantly reduced after treatment with metformin only in 43 cases (17.7%), metformin combined with other oral hypoglycemic drugs in 124 cases (51.0%) and metformin combined with insulin in 76 cases (31.3%). There was only 18.1% of the cases with normal range (> 80 ml/min) of creatinine clearance rate (Ccr), and 25.8% of the cases with Ccr

About this research paper

What this paper is about

OBJECTIVE: To evaluate the safety of metformin in the treatment of elderly type 2 diabetes mellitus (T2DM). METHODS: Two hundred and forty-three cases of elderly T2DM hospitalized from Jan. 1996 to Dec. 2006 were reviewed; the changes of fasting blood glucose(FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), liver and renal function and blood lactic acid were evaluate before and after treatment. RESULTS: The mean time of treatment with metformin was (6.6 +/- 3.9) years (3 months - 21 years) in these 243 cases. The levels of FBG, PBG and HbA1c significantly reduced after treatment with metformin only in 43 cases (17.7%), metformin combined with other oral hypoglycemic drugs in 124 cases (51.0%) and metformin combined with insulin in 76 cases (31.3%). There was only 18.1% of the cases with normal range (> 80 ml/min) of creatinine clearance rate (Ccr), and 25.8% of the cases with Ccr

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To evaluate the safety of metformin in the treatment of elderly type 2 diabetes mellitus (T2DM). METHODS: Two hundred and forty-three cases of elderly T2DM hospitalized from Jan. 1996 to Dec. 2006 were reviewed; the changes of fasting blood glucose(FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), liver and renal function and blood lactic acid were evaluate before and after treatment. RESULTS: The mean time of treatment with metformin was (6.6 +/- 3.9) years (3 months - 21 years) in these 243 cases. The levels of FBG, PBG and HbA1c significantly reduced after treatment with metformin only in 43 cases (17.7%), metformin combined with other oral hypoglycemic drugs in 124 cases (51.0%) and metformin combined with insulin in 76 cases (31.3%). There was only 18.1% of the cases with normal range (> 80 ml/min) of creatinine clearance rate (Ccr), and 25.8% of the cases with Ccr

Key concepts: Medicine, Metformin, Contraindication, Postprandial, Internal medicine, Lactic acidosis, Type 2 Diabetes Mellitus, Renal function

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
[Safety of metformin in the treatment of elderly type 2 diabetes mellitus]. — Research Paper | ScholarLens